10-K: Utah Medical Products Inc. Reports Lower 2024 Results Amid OEM Sales Decline and Filshie Clip Lawsuits

Utah Medical Products Inc. experienced a significant decrease in worldwide revenues and net income in 2024, primarily due to reduced OEM sales, declining Filshie clip sales, and ongoing product liability litigation.

Summary

• Utah Medical Products Inc. (UTMD) reported a decrease in consolidated financial performance for 2024, with worldwide revenues declining by 18.6% to $40.9 million compared to $50.2 million in 2023.
• Net income decreased by 16.6% to $13.874 million, and earnings per share (EPS) decreased by 13.4% to $3.961.
• The revenue decline was primarily attributed to a $5.9 million decrease in sales to PendoTECH (an OEM customer), a $2.1 million decrease in sales to OUS distributors (excluding Filshie), and a $1.5 million decrease in worldwide Filshie sales.
• Despite the revenue decline, UTMD maintained its gross profit margin at 59.0% due to reduced manufacturing personnel and closure of the assembly swing shift in Utah.
• Operating income margin remained relatively stable at 33.2%, benefiting from the amortization of the CSI intangible asset in 2023.
• The company repurchased 301,961 shares of its common stock for $19.968 million during 2024.
• UTMD anticipates a further revenue decrease of approximately $2 million (5%) in 2025, primarily due to a projected decline in sales to PendoTECH.
• The company projects 2025 operating income of about $12 million and estimates a combined income tax rate of around 19%, leading to a net income decrease of approximately 14% compared to 2024.
• UTMD returned $24.228 million to stockholders in the form of cash dividends and share repurchases in 2024, compared to $4.282 million in 2023.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company maintains a strong cash position and is actively managing capital allocation, it faces significant challenges including declining revenues, ongoing litigation, and increasing regulatory burdens. The outlook for 2025 is also negative, with projected revenue and net income decreases.

Positives

• Gross profit margin remained relatively stable at 59.0% despite the revenue decline.
• Operating income margin remained relatively stable at 33.2%, benefiting from the amortization of the CSI intangible asset in 2023.
• The company has a strong cash position, with $82.976 million in cash and investments at the end of 2024.
• UTMD is actively managing its capital allocation, returning cash to stockholders through dividends and share repurchases.
• The company is focused on innovation and new product development, with ongoing projects in various areas.

Negatives

• Worldwide revenues decreased by 18.6% in 2024.
• Net income decreased by 16.6% in 2024.
• Sales to PendoTECH, UTMD's largest OEM customer, declined significantly.
• Worldwide Filshie sales declined in 2024.
• The company is facing ongoing product liability litigation related to the Filshie Clip System.
• UTMD projects a further revenue decrease of approximately $2 million (5%) in 2025.

Risks

• Legislative or executive order healthcare interference in the United States renders the U.S. medical device marketplace unpredictable.
• Increasing regulatory burdens may result in significant loss of revenue and unpredictable costs.
• Group Purchasing Organizations (GPOs) in the U.S. add non-productive costs and weaken the company's marketing and sales efforts.
• A product liability lawsuit could result in significant legal expenses and a large award against the company.
• The company's reliance on third-party distributors in some markets may result in less predictable revenues.
• The loss of one or more key employees could negatively affect UTMD performance.
• Fluctuations in foreign currencies relative to the USD can result in significant differences in period-to-period financial results.
• Trade restrictions and/or tariffs resulting from changing government geopolitical trade policies have the potential to disrupt UTMD's supply chain and/or affect costs.

Future Outlook

UTMD anticipates a further revenue decrease of approximately $2 million (5%) in 2025, primarily due to a projected decline in sales to PendoTECH. The company projects 2025 operating income of about $12 million and estimates a combined income tax rate of around 19%, leading to a net income decrease of approximately 14% compared to 2024.

Management Comments

• UTMD's passion is in providing differentiated clinical solutions that will help improve the outcomes of medical procedures and reduce health risks, particularly for women and their babies.
• UTMD will continue to leverage its reputation as a device innovator and reliable manufacturer which will responsively take on challenges to work with clinicians who use its specialty devices.
• UTMD management is determined to recapture the longer-term performance.

Industry Context

The medical device industry is facing increasing regulatory burdens, cost pressures from GPOs, and challenges in accessing clinicians. Smaller companies like UTMD are at a competitive disadvantage due to these factors.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or comparable companies.
• The document mentions competitors but does not provide detailed performance comparisons.
• The document focuses on UTMD's specific challenges and strategies rather than benchmarking against industry peers.

Legal Proceedings

• Femcare Ltd. and its corporate parent Utah Medical Products, Inc. have been dismissed as defendants in CT.
• As of March 25, 2025, five cases have been thrown out by summary judgment with several others dismissed prior to the summary judgment phase.
• Three more summary judgment motions are pending in federal courts around the country, with decisions on those expected in 2025.
• Other summary judgment motions will be filed in 2025 after mandated discovery has been completed.

Stakeholder Impact

• Shareholders: The company is returning cash to shareholders through dividends and share repurchases, but the stock price has declined.
• Employees: The company has reduced manufacturing personnel to maintain profitability.
• Customers: The company is committed to providing differentiated clinical solutions and improving patient outcomes.
• Suppliers: The company is managing its supply chain to mitigate potential disruptions.
• Creditors: The company has a strong balance sheet with no bank debt.

Next Steps

• UTMD plans to exploit its pre-qualified status to introduce a line of high-pressure process control transducer configurations directly to biopharmaceutical manufacturers.
• UTMD plans to continue to leverage OUS distribution and manufacturing synergies by further integrating capabilities and resources in multinational operations.
• UTMD plans to focus on defending the proven safety and effectiveness of the Filshie Clip System in the U.S.
• UTMD plans to introduce additional products helpful to clinicians through product development.
• UTMD plans to continue to achieve excellent overall financial operating performance despite a contraction in revenues.
• UTMD plans to utilize positive cash generation to continue providing cash dividends to stockholders and make open market share repurchases if/ when the UTMD share price seems undervalued.
• UTMD plans to remain vigilant for affordable accretive acquisition opportunities which may be brought about by difficult economic conditions on small, innovative companies.

Key Dates

Keywords

Utah Medical Products, Filshie Clip, revenues, medical devices, OEM sales, net income, product liability, financial results, operating income, sales, UTMD